Why Capricor Therapeutics, Inc.’s (CAPR) Stock Is Up 5.31%
As of Wednesday, August 26, Capricor Therapeutics, Inc.’s CAPR share price has surged by 5.31%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.
Commentary & Analysis
Why Capricor Therapeutics, Inc.’s (CAPR) Stock Is Up 10.25%
As of Wednesday, August 26, Capricor Therapeutics, Inc.’s CAPR share price has surged by 10.25%, which has investors questioning if this is right time to sell.Omar Beirat
Why Capricor Therapeutics, Inc.’s (CAPR) Stock Is Up 21.03%
As of Tuesday, August 25, Capricor Therapeutics, Inc.’s CAPR share price has surged by 21.03%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Capricor Therapeutics, Inc.’s (CAPR) Stock Is Up 13.53%
As of Tuesday, August 25, Capricor Therapeutics, Inc.’s CAPR share price has surged by 13.53%, which has investors questioning if this is right time to sell.Tudor Pop
Why Capricor Therapeutics, Inc.’s (CAPR) Stock Is Up 8.11%
As of Monday, August 24, Capricor Therapeutics, Inc.’s CAPR share price has surged by 8.11%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | CAPR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $544.2 | $298.4 | 37% |
|
| Shares Out (Mil) | 57.9 | 54.0 | 51% |
|
| Institutional Ownership | 98.5% | 93.1% | 79% |
|
| Float (Mil) | 45.5 | 41.4 | 45% |
|
| Beta | 0.53 | 0.94 | 30% |
|
| Avg Daily Volume (000s) | 18,553 | 504 | 98% |
|
| Price Change (52-week) |
31.8% | 62.0% | 71% |
|
| Growth | CAPR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.0% | na |
|
| Net Income (5yr) | (50.3%) | (10.0%) | 7% |
|
| EPS (5yr) | (20.8%) | 16.0% | 13 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 26.3% | (15.6%) | 84% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 7 | 9 | |
| Current EPS | ($0.420) | ($2.276) | ($1.586) | |
| Month Ago EPS | $0.346 | ($0.222) | ($0.642) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | $0.473 | ($0.385) | ($0.764) | |
| Year/Year Chg | (40.3%) | 0.7% | (98.7%) | |
| Financials | CAPR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($129) | ($43) | 9% |
|
| EPS (TTM) | ($2.466) | ($1.400) | 13% |
|
| Operating Cash Flow (TTM) (Mil) | ($104) | ($32) | 6% |
|
| Net Cash Flow (TTM) (Mil) | ($2) | $2 | 37% |
|
| Long-Term Debt (Q1) (Mil) | $90 | $4 | 43% |
|
| Enterprise Value (Q1) (Mil) | $240 | $186 | 27% |
|
| Valuation | CAPR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.21 | 2.89 | 54% |
|
| P/E | na | 19.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | CAPR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.6% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (51.5%) | (47.6%) | 11% |
|
| ROE | (73.7%) | (55.0%) | 12% |
|
| Liabilities to Assets | 33.2% | 29.5% | 24% |
|
| F-Score | 3 | 3 | 18% |
|
Passing Stock Screens
As of 8/26/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Est Rev: Lowest 30 Down
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 2.9% |
| +/- S&P 500: | -4.6 |
FACTOR STRATEGY
Est Rev: Down 5% Screen
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 2.4% |
| +/- S&P 500: | -5.1 |
